Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06610227 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06610227 · ClinicalTrials.gov record · last posted 2025-07-16

A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors

StatusActive, Not Recruiting
PhaseEarly Phase 1
SponsorNING LI
Started2024-11-08
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 16, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This is an open-label, single-arm study to evaluate the safety and efficacy of multiple doses of SapRNA™-MICA/B Tumor Vaccine in patients with advanced solid tumors. Eligible patients will receive the monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection on Day 1, Day 14, and Day 28 respectively. Follow-up visits will be performed as scheduled after the end of treatment.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2024-09-20. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-07-13
Status change Not Yet Recruiting→Active, Not Recruitingv1
Trial Details
NCT Number NCT06610227
Lead Sponsor NING LI
Conditions Advanced Solid Tumors
Enrollment 18 participants
Start Date 2024-11-08
Primary Completion 2025-09-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-16